Stock Market Reviews

Read and share opinions on RCUS (Arcus Biosciences, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Arcus Biosciences, Inc. (NYSE:RCUS) Just Reported Earnings, And Analysts Cut Their Target Price
  Nov 1, 2025
• Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
  Oct 31, 2025
• Arcus Biosciences Announces Commencement of Public Offering of Common Stock
  Oct 30, 2025
• Why Arcus Biosciences (RCUS) May Be Banking on Partnerships to Accelerate Its Immuno-Oncology Pipeline
  Oct 30, 2025
• Arcus Biosciences (RCUS): Losses Widen 26% Annually, Revenue Growth Projections Test Bullish Outlook
  Oct 29, 2025
• Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Beats Revenue Estimates
  Oct 28, 2025
• Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
  Oct 28, 2025
• Arcus Biosciences (RCUS) Surges 7.5%: Is This an Indication of Further Gains?
  Oct 28, 2025
• Arcus Biosciences Inc. (RCUS) Posts Positive Results on Kidney Cancer Drug Trials
  Oct 26, 2025
• Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
  Oct 19, 2025
• Arcus Biosciences (RCUS) Is Up 14.9% After Positive Phase 2 Survival Data in Gastric Cancer—What's Changed
  Oct 14, 2025
• Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study
  Oct 12, 2025
• Arcus Biosciences Announces New Employment Inducement Grants
  Oct 9, 2025
• How Arcus Biosciences Aims To Take On Merck In Cancer Treatment
  Oct 7, 2025
• Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock?
  Oct 7, 2025
• A Fresh Look at Arcus Biosciences (RCUS) Valuation After New Casdatifan Data and Expanded Pipeline Initiatives
  Oct 7, 2025
• Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event
  Oct 6, 2025
• Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation
  Sep 2, 2025
• Arcus Biosciences to Participate in Three Upcoming Investor Conferences
  Aug 20, 2025